Suppression of Epidermal Growth Factor Receptor (EGFR) Expression by Small Hairpin RNA Inhibits the Growth of Human Nonsmall Cell Lung Cancers Bearing Wild-type and Mutant EGFR

REFERENCES

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341–354.
   PubMed Web of Science ®Google Scholar
• Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009;457:426–433.
   PubMed Web of Science ®Google Scholar
• McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002;3:737–747.
   PubMed Web of Science ®Google Scholar
• Paddison PJ, Caudy AA, Bernstein E. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948–958.
   PubMed Web of Science ®Google Scholar
• Sui G, Soohoo C, Affar el B. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 2002;99:5515–5520.
   PubMed Web of Science ®Google Scholar
• Yuan Y, Tan J, Wang Y. Chitosan nanoparticles as non-viral gene delivery vehicles based on atomic force microscopy study. Acta Biochim Biophys Sin (Shanghai) 2009;41:515–526.
   PubMed Web of Science ®Google Scholar
• Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release 2008;126:97–110.
   PubMed Web of Science ®Google Scholar
• Stabile LP, Lyker JS, Huang L. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 2004;11:325–335.
   PubMed Web of Science ®Google Scholar
• Yano J, Hirabayashi K, Nakagawa S. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10:7721–7726.
   PubMed Web of Science ®Google Scholar
• Sonoke S, Ueda T, Fujiwara K. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 2008;68:8843–8851.
   PubMed Web of Science ®Google Scholar
• La Monica S, Galetti M, Alfieri RR. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 2009;78:460–468.
   PubMed Web of Science ®Google Scholar
• Piao YJ, Jiang H, Xu J. Targeting the cancer-specific mutant EGF receptor with delta-24-river oncolytic adenovirus. Neuro Oncol 2006;8:416.
   Web of Science ®Google Scholar
• Heo DS, Park JG, Hata K. Evaluation of tetrazolium-based semiautomatic colorimetrie assay for measurement of human antitumor cytotoxicity. Cancer Res 1990;50:3681–3690.
   PubMed Web of Science ®Google Scholar
• Liu JJ, Huang RW, Lin DJ. Expression of survivin and bax/bcl-2 in peroxisome proliferator activated receptor-g ligands induces apoptosis on human myeloid leukemia cells in vitro. Ann Oncol 2005;16:455–459.
   PubMed Web of Science ®Google Scholar
• Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39–51.
   PubMed Web of Science ®Google Scholar
• Hata T, Furukawa T, Sunamura M. RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899–2905.
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Addiction to oncogenes-the Achilles heal of cancer. Science 2002;297:63–64.
   PubMed Web of Science ®Google Scholar
• Weinstein IB, Joe A. Oncogene addiction. Cancer Res 2008; 68:3077–3080.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Fukuoka M, Baselga J. Gefitinib—a novel targeted approach to treating cancer. Nat Rev Cancer 2004;4:956–965.
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–957.
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:225–235.
   Web of Science ®Google Scholar
• Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760–774.
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493–507.
   PubMed Web of Science ®Google Scholar
• Paez JG, Jänne PA, Lee JC. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–792.
   PubMed Web of Science ®Google Scholar
• Templeton NS, Lasic DD, Frederik PM. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997;15:647–652.
   PubMed Web of Science ®Google Scholar
• Christensen CL, Gjetting T, Poulsen TT. Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay. Clin Cancer Res 2010;16:2308–2319.
   PubMed Web of Science ®Google Scholar
• Lu C, Stewart DJ, Ji L. Systemic gene therapy with tumor suppressor FUS1-nanoparticles for recurrent/metastatic lung cancer. J Clin Oncol 2010;28:7582.
   Google Scholar
• Lu C, Stewart DJ, Ji L. A phase I trial of intravenous therapy with tumor suppressor FUS1-nanoparticles. J Clin Oncol 2009;27:e19065.
   Google Scholar
• Bean J, Brennan C, Shih JY. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007;104:20932–20937.
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–1043.
   PubMed Web of Science ®Google Scholar